Endo's 3Q Meets Expectations as Major Challenges Remain
While Endo continues to face a number of challenges from competition in both its branded and generic segments combined with ongoing mesh litigation, government opioid investigations, and high financial leverage, it reported third-quarter results that should keep year-end performance mostly in line with our expectations. Management expects year-end performance to come in at the high end of its revenue and earnings per share guidance ranges, but we don’t anticipate a major change in our fair value...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.